Table 1.
Classification of patients assessed for transplantation and distribution by phenotypes. Comparative clinical characteristics.
| Variable | Total N = 173 |
Non exacerbator N = 68 |
Exacerbator N = 100 |
ACO N = 5 |
p |
|---|---|---|---|---|---|
| Men | 137 (79.2) | 57 (83.8) | 76 (76) | 4 (80) | 0.47 |
| Age n(SD) | 59.7 (6.1) | 59.6 (5.5) | 60 (5.9) | 54.2 (14.6) | 0.11 |
| BMI | 25.4 (4.6) | 26.1 (4.7) | 24.9 (4.2) | 26.6 (5) | 0.19 |
| COPD characteristics | |||||
| Moderate exacerbations n(SD) | 0.4 (1.1) | 0.17 (0.6) | 0.8 (1.6) | 0 (0) | 0.0066 |
| Severe exacerbations n(SD) | 0.8 (1.4) | 0 (0) | 2 (1.8) | 1 (1.15) | <0.001 |
| Total exacerbations n(SD) | 1.2 (1.9) | 0.17 (0.7) | 2.91 (2.1) | 1 (1.15) | <0.001 |
| Dyspnea (mMRC) | 2.8 (0.7) | 2.9 (0.6) | 2.8 (0.7) | 3 (0) | 0.67 |
| FVC (%) | 61.1 (17) | 60.3 (15.2) | 61.8 (18.5) | 55.6 (13.6) | 0.66 |
| FEV1 (%) | 27.5 (9.9) | 26.4 (8.1) | 28.4 (11) | 25.6 (8.3) | 0.4 |
| DLCO (%) | 39.8 (17.3) | 43.6 (15.7) | 36.5 (18.4) | 38.6 (14) | 0.094 |
| 6MWT (m) | 230.1 (140.3) | 231. (126.6) | 228.6 (149.8) | 240 (160.2) | 0.98 |
| pO2 (mmHg) | 62.4 (10.9) | 63.1 (12.7) | 61.4 (9) | 69 (9.8) | 0.25 |
| pCO2 (mmHg) | 44.4 (7.4) | 44.7 (7.1) | 44.6 (7.8) | 38 (3.2) | 0.17 |
| BODE n(DE) | 6.6 (1.6) | 6.8 (1.5) | 6.5 (1.7) | 6.4 (1.1) | 0.5 |
| Sputum determination | 100 (57.8) | 46 (67.7) | 51 (51) | 3 (60) | 0.1 |
| Positive sputum cultures | 21 (21.9) | 12 (26.7) | 9 (18.4) | 0 (0) | 0.47 |
| Basal treatment | |||||
| LABA/ICS | 95 (67.4) | 33 (56.9) | 59 (74.7) | 3 (75) | 0.084 |
| LAMA/LABA | 8 (5.7) | 3 (5.2) | 4 (5) | 1 (25) | 0.24 |
| LAMA/LABA/ICS | 84 (48.5) | 30 (44.1) | 53 (53) | 1 (20) | 0.23 |
| Roflumilast | 18 (12.8) | 7 (12.1) | 10 (12.7) | 1 (25) | 0.76 |
| Azithromycin | 0 (0) | 0 (0) | 1 (25) | 0.7 | |
SD: standard deviation; ACO: asthma COPD overlap; BMI: body mass index; CVF: forced vital capacity; FEV1: forced espiratory volume in the first second; DLCO: carbon monoxide diffusion; 6MWT: six minute walking test; BODE: Body mass index, airflow Obstruction, Dyspnea and Excercise capacity index; LAMA: Long Acting Muscarinic Antagonist; LABA: Long Acting Beta Agonist; ICS: inhaled corticosteroids.